COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
Abstract Improving early diagnosis along with timely and effective treatment of COVID-19 are urgently needed. However, at present, the mechanisms underlying disease spread and development, defined prognosis, and immune status of patients with COVID-19 remain to be determined. Patients with severe di...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-02-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13048-021-00772-6 |
| _version_ | 1797972563323781120 |
|---|---|
| author | Antonio Macciò Sara Oppi Clelia Madeddu |
| author_facet | Antonio Macciò Sara Oppi Clelia Madeddu |
| author_sort | Antonio Macciò |
| collection | DOAJ |
| description | Abstract Improving early diagnosis along with timely and effective treatment of COVID-19 are urgently needed. However, at present, the mechanisms underlying disease spread and development, defined prognosis, and immune status of patients with COVID-19 remain to be determined. Patients with severe disease state exhibit a hyperinflammatory response associated with cytokine storm syndrome, hypercoagulability, and depressed cell-mediated immunity. These clinical manifestations, sharing similar pathogenesis, have been well-studied in patients with advanced ovarian cancer. The present review suggests treatment approaches for COVID-19 based on strategies used against ovarian cancer, which shares similar immunopathology and associated coagulation disorders. The chronicization of the hyperinflammatory cytokine storm in patients with severe COVID-19 highlights a defective resistance phase that leads to aspecific chronic inflammation, associated with oxidative stress, which impairs specific T-cell response, induces tissue and endothelial damage, and thrombosis associated with systemic effects that lead to severe multi-organ failure and death. These events are similar to those observed in advanced ovarian cancer which share similar pathogenesis mediated primarily by Interleukin-6, which is, as well demonstrated in ovarian cancer, the key cytokine driving the immunopathology, related systemic symptoms, and patient prognosis. Consistent with findings in other disease models with similar immunopathology, such as advanced ovarian cancer, treatment of severe COVID-19 infection should target inflammation, oxidative stress, coagulation disorders, and immunodepression to improve patient outcome. Correctly identifying disease stages, based on available laboratory data, and developing a specific protocol for each phase is essential for effective treatment. |
| first_indexed | 2024-04-11T03:50:29Z |
| format | Article |
| id | doaj.art-2277090fbde743d38146f2720126b4ac |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T03:50:29Z |
| publishDate | 2021-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-2277090fbde743d38146f2720126b4ac2023-01-02T01:58:04ZengBMCJournal of Ovarian Research1757-22152021-02-0114111610.1186/s13048-021-00772-6COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?Antonio Macciò0Sara Oppi1Clelia Madeddu2Department of Gynecologic Oncology, Businco Hospital, “Azienda di Rilievo Nazionale ad Alta Specializzazione G. Brotzu”Hematology and Transplant Center, Businco Hospital, “Azienda di Rilievo Nazionale ad Alta Specializzazione G. Brotzu”Department of Medical Sciences and Public Health, University of CagliariAbstract Improving early diagnosis along with timely and effective treatment of COVID-19 are urgently needed. However, at present, the mechanisms underlying disease spread and development, defined prognosis, and immune status of patients with COVID-19 remain to be determined. Patients with severe disease state exhibit a hyperinflammatory response associated with cytokine storm syndrome, hypercoagulability, and depressed cell-mediated immunity. These clinical manifestations, sharing similar pathogenesis, have been well-studied in patients with advanced ovarian cancer. The present review suggests treatment approaches for COVID-19 based on strategies used against ovarian cancer, which shares similar immunopathology and associated coagulation disorders. The chronicization of the hyperinflammatory cytokine storm in patients with severe COVID-19 highlights a defective resistance phase that leads to aspecific chronic inflammation, associated with oxidative stress, which impairs specific T-cell response, induces tissue and endothelial damage, and thrombosis associated with systemic effects that lead to severe multi-organ failure and death. These events are similar to those observed in advanced ovarian cancer which share similar pathogenesis mediated primarily by Interleukin-6, which is, as well demonstrated in ovarian cancer, the key cytokine driving the immunopathology, related systemic symptoms, and patient prognosis. Consistent with findings in other disease models with similar immunopathology, such as advanced ovarian cancer, treatment of severe COVID-19 infection should target inflammation, oxidative stress, coagulation disorders, and immunodepression to improve patient outcome. Correctly identifying disease stages, based on available laboratory data, and developing a specific protocol for each phase is essential for effective treatment.https://doi.org/10.1186/s13048-021-00772-6Ovarian cancerCOVID-19ImmunopathologyResistanceToleranceInterleukin-6 |
| spellingShingle | Antonio Macciò Sara Oppi Clelia Madeddu COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? Journal of Ovarian Research Ovarian cancer COVID-19 Immunopathology Resistance Tolerance Interleukin-6 |
| title | COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? |
| title_full | COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? |
| title_fullStr | COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? |
| title_full_unstemmed | COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? |
| title_short | COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied? |
| title_sort | covid 19 and cytokine storm syndrome can what we know about interleukin 6 in ovarian cancer be applied |
| topic | Ovarian cancer COVID-19 Immunopathology Resistance Tolerance Interleukin-6 |
| url | https://doi.org/10.1186/s13048-021-00772-6 |
| work_keys_str_mv | AT antoniomaccio covid19andcytokinestormsyndromecanwhatweknowaboutinterleukin6inovariancancerbeapplied AT saraoppi covid19andcytokinestormsyndromecanwhatweknowaboutinterleukin6inovariancancerbeapplied AT cleliamadeddu covid19andcytokinestormsyndromecanwhatweknowaboutinterleukin6inovariancancerbeapplied |